Table 2. Seroprevalence of DENV infection and subgroup analysis.
| Characteristics | African Region (%) | Eastern Mediterranean Region (%) | European Region (%) | South-East Asian Region (%) | Region of the Americas (%) | Western Pacific Region (%) | Overall (%) |
|---|---|---|---|---|---|---|---|
| Development stage | |||||||
| Developed | / | / | 4 (0–7) | / | 42 (12–71) | / | 30 (15–46) |
| Developing | 12 (8–15) | 27 (21–34) | / | 56 (39–73) | 52 (35–68) | 27 (19–35) | 38 (31–44) |
| Area | |||||||
| Urban | 11 (5–17) | 34 (20–48) | / | 65 (55–74) | 50 (29–70) | 17 (9–24) | 39 (30–49) |
| Rural | 14 (12–16) | 20 (15–26) | / | 33 (21–45) | 22 (17–27) | 20 (7–33) | 23 (15–32) |
| Study date | |||||||
| 2000–2009 | 15 (11–19) | 10 (1–18) | / | 27 (0–75) | 65 (51–79) | 26 (9–42) | 40 (25–54) |
| 2010–2019 | 7 (4–11) | 28 (22–33) | 4 (0–7) | 64 (51–76) | 42 (25–59) | 28 (16–39) | 37 (29–44) |
| Age | |||||||
| Adults | 14 (12–16) | 37 (22–52) | / | 59 (52–66) | 56 (8–100) | 40 (19–61) | 44 (28–59) |
| Children | 13 (-1-28) | 25 (21–29) | / | 50 (34–66) | 42 (22–63) | 30 (5–56) | 38 (26–50) |
| Population | |||||||
| Blood donors | / | / | / | / | / | / | 52 (26–78) |
| Pregnant women | / | / | / | / | / | / | 27 (11–44) |
| General population | 13 (7–18) | 27 (19–35) | 6 (0–12) | 56 (14–97) | 54 (29–79) | 26 (14–37) | 33 (26–41) |
| Immunoglobulin | |||||||
| IgG | 13 (8–17) | 29 (23–34) | 4 (0–7) | 59 (47–70) | 54 (40–69) | 28 (19–36) | 39 (33–46) |
| IgM | 4 (0–10) | 5 (4–6) | 0 (0–1) | 4 (1–7) | 6 (3–9) | 4 (3–5) | 4 (3–5) |
| Inapparent proportion | 58 (51–66) | 19 (17–21) | / | 93 (89–98) | 79 (70–88) | 90 (83–96) | 80 (72–88) |